Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Grupo Espanol de Tumores Neuroendocrinos
Exelixis
SAPU NANO (US) LLC
RayzeBio, Inc.
M.D. Anderson Cancer Center
ITM Solucin GmbH
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
ITM Solucin GmbH
Grupo Espanol de Tumores Neuroendocrinos
Novartis
Memorial Sloan Kettering Cancer Center
Federation Francophone de Cancerologie Digestive
AC Camargo Cancer Center
Emory University
Novartis
Novartis
AIO-Studien-gGmbH
National Institutes of Health Clinical Center (CC)
University of Kentucky
Eli Lilly and Company
Novartis
Novartis
Emory University
King Faisal Specialist Hospital & Research Center
University of Cincinnati
Novartis
Dana-Farber Cancer Institute
Novartis
M.D. Anderson Cancer Center
Novartis
Guangdong Provincial People's Hospital